Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives $48.40 Average Target Price from Analysts

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) has received an average rating of “Buy” from the seven research firms that are covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $48.40.

Several equities analysts have recently weighed in on AAPG shares. Oppenheimer assumed coverage on Ascentage Pharma Group International in a report on Thursday, December 4th. They set an “outperform” rating and a $45.00 target price for the company. Rodman & Renshaw initiated coverage on shares of Ascentage Pharma Group International in a report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price target on the stock. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. Finally, Truist Financial set a $51.00 price objective on shares of Ascentage Pharma Group International in a research note on Monday, November 24th.

Ascentage Pharma Group International Stock Performance

AAPG stock opened at $24.22 on Thursday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53. The stock has a 50-day moving average price of $25.13 and a two-hundred day moving average price of $31.36. Ascentage Pharma Group International has a 12-month low of $17.56 and a 12-month high of $48.45.

Institutional Trading of Ascentage Pharma Group International

Several large investors have recently added to or reduced their stakes in AAPG. Mirae Asset Global Investments Co. Ltd. purchased a new position in Ascentage Pharma Group International in the third quarter valued at about $96,000. ABC Arbitrage SA acquired a new stake in shares of Ascentage Pharma Group International in the third quarter valued at about $204,000. Citadel Advisors LLC acquired a new stake in shares of Ascentage Pharma Group International in the third quarter valued at about $383,000. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International during the 2nd quarter valued at about $391,000. Finally, Tema Etfs LLC acquired a new position in Ascentage Pharma Group International during the 2nd quarter worth approximately $610,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.